A new drug for the treatment of Waldenström Macroglobulinemia (lymphoplasmacytic lymphoma) will soon be reviewed by the pan-Canadian Oncology Drug Review (pCODR):
- Ibrutinib (Imbruvica) for the treatment of patients with Waldenström Macroglobulinemia who have received at least one prior treatment.
Please note: This survey is for caregivers.
pCODR makes recommendations to the provinces and territories to help them decide whether they will provide funding for new cancer drugs. Understanding the experiences of patients and their caregivers is a key element in the pCODR review process and pCODR allows patient groups to do this through "patient and caregiver submissions".
The purpose of this survey is to help Lymphoma Canada and the Canadian Organization for Rare Disorders (CORD) develop a complete and thorough submission to pCODR and provincial governments. Patient and caregiver input is essential, as pCODR needs to consider the opinions and experiences of those who will be most directly affected by all drug funding recommendations they make.
As a caregiver of a person with Waldenström Macroglobulinemia, we invite you to complete this survey to help pCODR better understand your experience. Your participation in this survey is important as it may help improve access to this new drug for patients in Canada. The greater the response to this survey, the better
our submission will be to pCODR.
You do not have to be a Canadian resident to respond to this survey; we appreciate input from all caregivers of people with Waldenström Macroglobulinemia.
We at Lymphoma Canada and the Canadian Organization for Rare Disorders (CORD) thank you in advance for your contribution and greatly appreciate your participation in this survey. If you have any questions, concerns, or technical difficulties while completing this survey please contact Elizabeth Lye at: firstname.lastname@example.org
The deadline to complete this survey is Wednesday, April 27th, midnight Pacific Time.